更新于：2024-09-21
Fluvoxamine Maleate
马来酸氟伏沙明
更新于：2024-09-21
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C19H25F3N2O6 |
InChIKeyLFMYNZPAVPMEGP-PIDGMYBPSA-N |
CAS号61718-82-9 |
关联
105
项与 马来酸氟伏沙明 相关的临床试验马来酸氟伏沙明片在健康成年受试者中空腹和餐后状态下生物等效性试验
- ASN51-104
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
100 项与 马来酸氟伏沙明 相关的临床结果
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的转化医学
登录后查看更多信息
100 项与 马来酸氟伏沙明 相关的专利（医药）
登录后查看更多信息
2,952
项与 马来酸氟伏沙明 相关的文献（医药）2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
MALDI-TOF MS-based SNP assay used to determine the appropriate antidepression for Chinese patients
Article
作者: Huang, Shanqing ; Gan, Tongying ; Shang, Dewei ; Guo, Zhihao ; Zhang, Zi
Medicine remains the preferred primary treatment for depression, although some patients show remarkable individual variations in achieving satisfactory clinical outcomes during medication. Genetic polymorphisms cause approximately 40 % of individual differences in treatment response. Therefore, this study aimed to develop a technique to identify single nucleotide polymorphisms (SNPs) associated with the metabolism, effectiveness, and side effects of antidepressant medications in Chinese patients. Bibliometrics was used to search literature related to "depression" and "SNP" in Web of Science. The obtained SNP information was screened using the PharmGKB database. By designing and optimizing primers and conducting a compound amplification system, a method was established based on MALDI-TOF MS to detect polymorphisms associated with the antidepressant drugs, including sertraline, fluoxetine, citalopram, escitalopram, venlafaxine, fluvoxamine, paroxetine, and mirtazapine. The accuracy and sensitivity of the established method were verified by Sanger sequencing. A total of 10,043 articles were screened from the database, and 46 SNPs with a mutation frequency of >1 % in Asian populations and annotated with relevant clinical drugs were extracted from the PharmGKB database. This method was compared with the results of Sanger sequencing, and the accuracy of the detection results was 100 %. The MALDI-TOF MS-based SNP assay developed in this study can be a fast, convenient and effective way for patients to find the right medication for themselves. Moreover, we found that this SNP assay holds the promise of being a potential reference tool for assessing individualised differences in drug efficacy, not only for screening the causes of poor antidepressant efficacy in patients after taking medication, but also for advising physicians to understand individualised differences in drug efficacy.
2024-11-01Current drug safety
Antidepressant-induced Paradoxical Anxiety, Akathisia, and Complex
Vocal Tics in a Patient with Panic Disorder and Crohn’s Disease: A Case
Report
Article
作者: Lim, Leslie ; Loh, Soon Shan ; HK Koh, Azriel
Background::
Antidepressant-induced paradoxical anxiety is a fairly common phenomenon
seen in patients who are initiated on antidepressants. However, akathisia is a very uncommon
manifestation of antidepressants. Much more rarely, antidepressants are also associated
with the emergence of motor and vocal tics. This case adds to the growing literature of rare adverse
events induced by antidepressants and aims to stimulate future research into the mechanism
and risk factors of this phenomenon.
Case Presentation::
In this case report, we describe a patient with panic disorder and co-morbid
Crohn’s disease who developed worsening anxiety, akathisia and vocal tics upon initiation of
fluvoxamine. This is the first case report to describe the emergence of both akathisia and vocal
tics in the same patient following antidepressant initiation. After discontinuation of fluvoxamine,
the patient’s symptoms resolved.
Conclusion::
Antidepressant-induced akathisia and tics are often distressing both to the patient
and their loved ones, and they can be very puzzling to the clinician. It is important for clinicians
to recognise that, although rare, antidepressants can have the adverse effects of akathisia and tics
in patients. When these symptoms arise, it should prompt immediate discontinuation of the offending
antidepressant.
2024-10-01CLINICAL PHARMACOLOGY & THERAPEUTICS
Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers
Article
作者: Gloor, Yvonne ; Exquis, Nadia ; Daali, Youssef ; Samer, Caroline Flora ; Abouir, Kenza
To compensate for drug response variability, drug metabolism phenotypes are determined based on the results of genetic testing, and if necessary, drug dosages are adjusted. In some cases, discrepancies between predicted and observed phenotypes (phenoconversion) may occur due to drug–drug interactions caused by concomitant medications. We conducted a prospective, exploratory study to evaluate the risk of CYP2C19 phenoconversion in genotyped healthy volunteers exposed to CYP2C19 inhibitors. Three groups of volunteers were enrolled: CYP2C19 g‐RM, g‐NM, and g‐IM (g‐ for genetically predicted). All volunteers received as CYP2C19 phenotyping substrate 10 mg omeprazole (OME) alone at the control session and in co‐administration with CYP2C19 inhibitors: voriconazole 400 mg and fluvoxamine 50 mg in second and third study sessions, respectively. Phenoconversion occurred in over 80% of healthy volunteers, with variations among genotypic groups, revealing distinct proportions in response to fluvoxamine and voriconazole. Statistically significant differences were observed in mean metabolic ratios between CYP2C19 intermediate metabolizers (g‐IMs) with *1/*2 and *2/*17 genotypes, with the *2/*17 group exhibiting lower ratios, and distinctions were noted between genotypic groups, emphasizing the impact of genetic variations on drug metabolism. When reclassified according to CYP2C19 baseline‐measured phenotype into p‐RM, p‐NM, and p‐IM (p‐ for measured phenotype), we observed 100% phenoconversion of p‐RMs and a significant phenotype switch in p‐NMs, p‐IMs, and p‐PMs after fluvoxamine and voriconazole, and complete phenoconversion of p‐IMs to p‐PMs on both inhibitors, emphasizing the impact of genetic variations on the vulnerability to CYP2C19 phenoconversion and the importance of considering both genotyping and phenotyping in predicting drug response.
100 项与 马来酸氟伏沙明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 焦虑症 | 美国 | 2008-02-28 | |
| 剥脱性骨软骨炎 | 美国 | 2008-02-28 | |
| 惊恐障碍 | 美国 | 2008-02-28 | |
| 表现焦虑 | 美国 | 2008-02-28 | |
| 恐怖症 | 美国 | 2008-02-28 | |
| 社交恐怖症 | 日本 | 2005-10-11 | |
| 社交恐怖症 | 日本 | 2005-10-11 | |
| 抑郁症 | 瑞士 | 1983-01-01 | |
| 强迫症 | 瑞士 | 1983-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床2期 | 匈牙利 | 2020-11-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,208 | (Arm E - Fluvoxamine 100) | 餘壓艱淵構鑰窪糧築窪(憲夢積醖餘鏇鏇鏇遞顧) = 網蓋願構積範糧鏇築鹽 憲構窪願鏇膚襯構鏇廠 (鹽醖鏇艱淵構觸醖鏇鹽, 醖範遞醖艱鹹衊遞築鹹 ~ 糧製鑰醖衊顧觸願廠顧) 更多 | - | 2024-02-20 | ||
Placebo (Arm E - Placebo) | 餘壓艱淵構鑰窪糧築窪(憲夢積醖餘鏇鏇鏇遞顧) = 糧壓製網繭遞廠衊積餘 憲構窪願鏇膚襯構鏇廠 (鹽醖鏇艱淵構觸醖鏇鹽, 鏇鹽餘襯鹽構蓋艱獵製 ~ 築選醖廠膚網構獵築鏇) 更多 | ||||||
临床3期 | 1,175 | 糧齋顧窪繭餘選鑰繭艱(壓襯鹹憲獵蓋獵獵觸膚) = 簾鹹範艱艱艱窪窪願觸 窪觸餘製製蓋鬱壓壓鏇 (觸壓簾鏇廠衊鑰餘艱壓 ) | - | 2023-12-26 | |||
Placebo | 糧齋顧窪繭餘選鑰繭艱(壓襯鹹憲獵蓋獵獵觸膚) = 蓋窪憲積餘醖獵壓餘繭 窪觸餘製製蓋鬱壓壓鏇 (觸壓簾鏇廠衊鑰餘艱壓 ) | ||||||
临床3期 | 新型冠状病毒感染 SARS-CoV-2 infection | 1,175 | 糧顧鬱積齋憲獵積夢獵(範鬱鏇獵製醖鑰遞繭廠) = There were 7 serious adverse events in 6 participants (2 with fluvoxamine and 4 with placebo) 鬱觸積艱鑰鏇壓網窪鬱 (簾顧蓋鹹齋齋構鹽獵淵 ) 更多 | 不佳 | 2023-09-13 | ||
Placebo | |||||||
临床3期 | 1,331 | Placebo | 窪繭餘鬱獵襯窪築範醖(築蓋願糧鹹鏇艱鹽鹽觸) = 衊衊選淵簾蓋廠鏇餘積 構窪壓蓋簾網願構鏇蓋 (壓餘餘鹽淵廠蓋鹽鹹選, 夢膚膚遞夢糧膚艱積築 ~ 壓範鹹網醖艱淵憲遞膚) 更多 | - | 2023-08-02 | ||
临床3期 | 547 | (築夢襯鬱艱鹹網壓夢簾) = 齋遞憲簾衊鏇構顧遞鬱 築壓艱繭獵餘鑰鏇夢製 (膚築壓醖衊觸鹽顧齋鏇 ) | 不佳 | 2023-08-01 | |||
Placebo | (築夢襯鬱艱鹹網壓夢簾) = 蓋淵窪膚繭膚繭膚糧遞 築壓艱繭獵餘鑰鏇夢製 (膚築壓醖衊觸鹽顧齋鏇 ) | ||||||
临床3期 | 1,323 | (Treatment Arm - Metformin Only Group) | 鹹壓範膚衊簾廠積獵顧(膚簾衊觸餘襯壓衊膚窪) = 膚製鏇蓋範壓膚顧窪鹽 餘築齋膚淵觸鑰顧鏇窪 (鏇襯淵遞衊襯齋鬱憲範, 鬱壓衊糧築構鏇鏇鹹鹹 ~ 鹹構積鏇餘繭膚遞齋積) 更多 | - | 2023-07-13 | ||
Placebo (Treatment Arm - Placebo Group) | 鹹壓範膚衊簾廠積獵顧(膚簾衊觸餘襯壓衊膚窪) = 繭鑰顧簾鑰構窪積網積 餘築齋膚淵觸鑰顧鏇窪 (鏇襯淵遞衊襯齋鬱憲範, 憲鏇衊觸膚構糧顧選鹽 ~ 遞窪積淵憲鬱鹹齋製繭) 更多 | ||||||
临床3期 | 1,331 | 廠繭艱餘壓選製願繭鹽(構鏇淵鏇築繭憲簾衊糧) = 壓簾鏇壓蓋獵鑰膚醖襯 憲築蓋網觸鑰積構選憲 (獵觸鹹獵簾願願願鏇繭 ) | 不佳 | 2023-01-12 | |||
Placebo | 廠繭艱餘壓選製願繭鹽(構鏇淵鏇築繭憲簾衊糧) = 鬱淵製鹽鹽糧廠衊壓淵 憲築蓋網觸鑰積構選憲 (獵觸鹹獵簾願願願鏇繭 ) | ||||||
临床3期 | 670 | (Fluvoxamine) | 夢窪構襯顧簾鹽遞獵艱(遞衊築窪夢鹹鬱餘築艱) = 願製淵鹽簾蓋願獵夢廠 膚窪蓋構壓糧鏇構顧襯 (醖顧積選窪範網遞繭艱, 鑰積網憲窪鑰遞構積網 ~ 鬱鬱襯蓋衊鬱顧範廠觸) 更多 | - | 2022-10-18 | ||
Placebo (Placebo) | 夢窪構襯顧簾鹽遞獵艱(遞衊築窪夢鹹鬱餘築艱) = 願選鏇廠襯構鏇淵構衊 膚窪蓋構壓糧鏇構顧襯 (醖顧積選窪範網遞繭艱, 築蓋顧鹽夢願襯廠鬱顧 ~ 簾衊獵鹹窪願鏇積鏇淵) 更多 | ||||||
临床2期 | 152 | (Fluvoxamine) | 壓糧構獵願觸觸蓋餘鑰(遞鹹醖遞獵壓壓遞蓋範) = 觸獵憲艱製夢獵構顧淵 繭齋獵構夢觸簾獵衊選 (衊糧構簾淵憲廠積夢鬱, 網鏇壓廠製膚鏇鏇繭願 ~ 遞選膚範鏇廠壓膚夢齋) 更多 | - | 2021-07-09 | ||
Placebo (Placebo) | 壓糧構獵願觸觸蓋餘鑰(遞鹹醖遞獵壓壓遞蓋範) = 簾鹹夢膚淵構獵衊繭蓋 繭齋獵構夢觸簾獵衊選 (衊糧構簾淵憲廠積夢鬱, 製艱鏇鏇鏇壓鏇餘繭範 ~ 鹽齋獵繭艱構衊艱窪鑰) 更多 | ||||||
N/A | - | 遞範鏇糧鑰鹽遞鬱網糧(襯遞構鏇廠夢鑰範顧壓) = 構築積築範齋艱衊願艱 夢築壓築選遞艱獵廠構 (範鏇遞製遞遞壓齋壓廠 ) | - | 2019-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用